0.1 C
New York
Wednesday, January 15, 2025

In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

156,242FansLike
396,312FollowersFollow
2,340SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x